Difference between revisions of "Team:EPFL"

Line 16: Line 16:
 
     <p style="font-size:20px;">While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of cancer therapy. Cancer immunotherapy is becoming a key technique for the successful fight against cancer. The goal of cancer immunotherapy
 
     <p style="font-size:20px;">While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of cancer therapy. Cancer immunotherapy is becoming a key technique for the successful fight against cancer. The goal of cancer immunotherapy
 
       is to harness the immune system in the fight against cancer. The project that the EPFL 2018 iGEM team is presenting is focused on the development of a new therapeutic approach to target specific types of cancer using immunotherapy methods, with
 
       is to harness the immune system in the fight against cancer. The project that the EPFL 2018 iGEM team is presenting is focused on the development of a new therapeutic approach to target specific types of cancer using immunotherapy methods, with
       a focus on vaccines. Furthermore, the project aims to integrate the personalized medicine approaches, by using patient-specific neoantigens to trigger the immune system and produce the response against cancer. The project is exhaustive and can
+
       a focus on vaccines. Furthermore, the project aims to integrate the personalized medicine approaches, by using patient-specific neoantigens to trigger the immune system and produce the response against cancer. The project is exhaustive and can be
       be divided into the following parts:</p>
+
       divided into the following parts:</p>
 
     <br>
 
     <br>
    <div class="row">
+
  </div>
      <div class="col-sm-3">
+
 
        <p><strong>Detection of cancer patient specific tumor mutations and neoantigens</strong></p>
+
 
        <img src="https://static.igem.org/mediawiki/2018/b/b0/T--EPFL--Detection.png" class="img-circle project_part" alt="detection" width="255" height="255">
+
  <div class="container-fluid text-center">
       </div>
+
    <div class="col-sm-3">
      <div class="col-sm-3">
+
      <img src="https://static.igem.org/mediawiki/2018/b/b0/T--EPFL--Detection.png" class="img-circle project_part" alt="detection" width="255" height="255">
        <p><strong>Expression of the neoantigens and the adjuvant using encapsulin</strong></p>
+
       <p><strong>Detection of cancer patient specific tumor mutations and neoantigens</strong></p>
        <img src="https://static.igem.org/mediawiki/2018/9/93/T--EPFL--vaccine.png" class="img-circle project_part" alt="Vaccine" width="255" height="255">
+
    </div>
       </div>
+
    <div class="col-sm-3">
      <div class="col-sm-3">
+
      <img src="https://static.igem.org/mediawiki/2018/9/93/T--EPFL--vaccine.png" class="img-circle project_part" alt="Vaccine" width="255" height="255">
        <p><strong>Maturation of dendritic cells and T-cells <br> <br></strong></p>
+
       <p><strong>Expression of the neoantigens and the adjuvant using encapsulin</strong></p>
        <img src="https://static.igem.org/mediawiki/2018/1/1f/T--EPFL--Dendritic.png" class="img-circle project_part" alt="Dendritic" width="255" height="255">
+
    </div>
       </div>
+
    <div class="col-sm-3">
      <div class="col-sm-3">
+
      <img src="https://static.igem.org/mediawiki/2018/1/1f/T--EPFL--Dendritic.png" class="img-circle project_part" alt="Dendritic" width="255" height="255">
        <p><strong>Detection of cancer relapse using liquid biopsies of ctDNA and cancer miRNA</strong></p>
+
       <p><strong>Maturation of dendritic cells and T-cells</strong></p>
        <img src="https://static.igem.org/mediawiki/2018/3/3c/T--EPFL--follow_up.png" class="img-circle project_part" alt="follow_up" width="255" height="255">
+
    </div>
       </div>
+
    <div class="col-sm-3">
 +
      <img src="https://static.igem.org/mediawiki/2018/3/3c/T--EPFL--follow_up.png" class="img-circle project_part" alt="follow_up" width="255" height="255">
 +
       <p><strong>Detection of cancer relapse using liquid biopsies of ctDNA and cancer miRNA</strong></p>
 
     </div>
 
     </div>
 
   </div>
 
   </div>
 +
  
 
</body>
 
</body>
  
 
</html>
 
</html>

Revision as of 17:44, 1 August 2018

iGEM EPFL 2018

CAPOEIRA

encapsulin

Cancer Personalized Encapsulin Immunotherapy and Relapse Assay


What is CAPOEIRA ?

While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of cancer therapy. Cancer immunotherapy is becoming a key technique for the successful fight against cancer. The goal of cancer immunotherapy is to harness the immune system in the fight against cancer. The project that the EPFL 2018 iGEM team is presenting is focused on the development of a new therapeutic approach to target specific types of cancer using immunotherapy methods, with a focus on vaccines. Furthermore, the project aims to integrate the personalized medicine approaches, by using patient-specific neoantigens to trigger the immune system and produce the response against cancer. The project is exhaustive and can be divided into the following parts:


detection

Detection of cancer patient specific tumor mutations and neoantigens

Vaccine

Expression of the neoantigens and the adjuvant using encapsulin

Dendritic

Maturation of dendritic cells and T-cells

follow_up

Detection of cancer relapse using liquid biopsies of ctDNA and cancer miRNA